These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 38480689)

  • 21. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.
    Wang L; Møhlenberg M; Wang P; Zhou H
    Cytokine Growth Factor Rev; 2023 Apr; 70():13-25. PubMed ID: 36948931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continued evasion of neutralizing antibody response by Omicron XBB.1.16.
    Faraone JN; Qu P; Zheng YM; Carlin C; Jones D; Panchal AR; Saif LJ; Oltz EM; Gumina RJ; Liu SL
    Cell Rep; 2023 Oct; 42(10):113193. PubMed ID: 37777967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera.
    Lee J; Naoe Y; Bang U; Nakagama Y; Saito A; Kido Y; Hotta A
    Virology; 2024 Jul; 595():110067. PubMed ID: 38653156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.
    Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL
    Cell; 2024 Feb; 187(3):585-595.e6. PubMed ID: 38194968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
    Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
    Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3.
    Liu Y; Zhao X; Shi J; Wang Y; Liu H; Hu YF; Hu B; Shuai H; Yuen TT; Chai Y; Liu F; Gong HR; Li J; Wang X; Jiang S; Zhang X; Zhang Y; Li X; Wang L; Hartnoll M; Zhu T; Hou Y; Huang X; Yoon C; Wang Y; He Y; Zhou M; Du L; Zhang X; Chan WM; Chen LL; Cai JP; Yuan S; Zhou J; Huang JD; Yuen KY; To KK; Chan JF; Zhang BZ; Sun L; Wang P; Chu H
    Nat Commun; 2024 Oct; 15(1):8728. PubMed ID: 39379369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China.
    Zhao XJ; Liu XL; Liang YM; Zhang S; Liu T; Li LB; Jiang WG; Chen JJ; Xu Q; Lv CL; Jiang BG; Kou ZQ; Wang GL; Fang LQ
    J Med Virol; 2024 May; 96(5):e29640. PubMed ID: 38699969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
    Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG
    EBioMedicine; 2023 Apr; 90():104545. PubMed ID: 37002990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic diversity and genomic epidemiology of SARS-CoV-2 during the first 3 years of the pandemic in Morocco: comprehensive sequence analysis, including the unique lineage B.1.528 in Morocco.
    Djorwé S; Malki A; Nzoyikorera N; Nyandwi J; Zebsoubo SP; Bellamine K; Bousfiha A
    Access Microbiol; 2024; 6(10):. PubMed ID: 39376591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Balancing Functional Tradeoffs between Protein Stability and ACE2 Binding in the SARS-CoV-2 Omicron BA.2, BA.2.75 and XBB Lineages: Dynamics-Based Network Models Reveal Epistatic Effects Modulating Compensatory Dynamic and Energetic Changes.
    Verkhivker G; Alshahrani M; Gupta G
    Viruses; 2023 May; 15(5):. PubMed ID: 37243229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants.
    Tamura T; Ito J; Uriu K; Zahradnik J; Kida I; Anraku Y; Nasser H; Shofa M; Oda Y; Lytras S; Nao N; Itakura Y; Deguchi S; Suzuki R; Wang L; Begum MM; Kita S; Yajima H; Sasaki J; Sasaki-Tabata K; Shimizu R; Tsuda M; Kosugi Y; Fujita S; Pan L; Sauter D; Yoshimatsu K; Suzuki S; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Yamamoto Y; Nagamoto T; Schreiber G; Maenaka K; ; Hashiguchi T; Ikeda T; Fukuhara T; Saito A; Tanaka S; Matsuno K; Takayama K; Sato K
    Nat Commun; 2023 May; 14(1):2800. PubMed ID: 37193706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact.
    Sil D; Gautam S; Saxena S; Joshi S; Kumar D; Mehta A; Jindal P; Sharma S; Pandey P; Diksha ; Singh A
    Curr Drug Targets; 2024; 25(8):517-525. PubMed ID: 38726782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants.
    Johnston TS; Li SH; Painter MM; Atkinson RK; Douek NR; Reeg DB; Douek DC; Wherry EJ; Hensley SE
    Immunity; 2024 Apr; 57(4):912-925.e4. PubMed ID: 38490198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal Analysis of Humoral and Cellular Immune Response up to 6 Months after SARS-CoV-2 BA.5/BF.7/XBB Breakthrough Infection and BA.5/BF.7-XBB Reinfection.
    Wang X; Zhang M; Wei K; Li C; Yang J; Jiang S; Zhao C; Zhao X; Qiao R; Cui Y; Chen Y; Li J; Cai G; Liu C; Yu J; Zhang W; Xie F; Wang P; Zhang Y
    Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
    Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
    J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1.
    Liu S; Liang Z; Nie J; Gao WB; Li X; Zhang L; Yu Y; Wang Y; Huang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2225638. PubMed ID: 37313604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1.
    Sohail MS; Ahmed SF; Quadeer AA; McKay MR
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tracking SARS-CoV-2 variants during the 2023 flu season and beyond in Lebanon.
    Kodsi IA; Rayes DE; Koweyes J; Khoury CA; Rahy K; Thoumi S; Chamoun M; Haddad H; Mokhbat J; Tokajian S
    Virus Res; 2024 Jan; 339():199289. PubMed ID: 38036064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A long-term cohort study: the immune evasion and decreasing neutralization dominated the SARS-CoV-2 breakthrough infection.
    Liu Q; Jin M; Mei F; Fan H; Gu M; Zhang Y; Qian S; Tan X; Ji L; Zhang Z; Chen G; Yan H; Chen Y; Lan K; Geng Q; Cai K; Zhou L
    Front Cell Infect Microbiol; 2024; 14():1381877. PubMed ID: 38572316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination.
    Ju B; Fan Q; Liu C; Shen S; Wang M; Guo H; Zhou B; Ge X; Zhang Z
    Cell Rep; 2023 Jun; 42(6):112532. PubMed ID: 37219999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.